Biotherapy of Breast Cancer with EGF-Genistein

Abstract

The major goal of this research project was to optimize the conjugation procedures used in the preparation of the EGF-Gen conjugates in order to overcome the major limitations of this technology, including (1) instability of the conjugates; (2) presence of Gen-free modified EGF in the conjugate preparations; (3) slow kinetics of cell kill; and (4) low yield of intact conjugate. The research did not lead to a solution for any of the above listed problems/limitations of the technology. It is therefore unlikely that the Genistein conjugates of EGF will be clinically useful. We have explored the potential of EGF conjugates containing other more active inhibitors of the EGF tyrosine kinase. While these conjugates have not been tested in animal models of breast cancer during the term of this grant, they are unlikely to offer significant advantages over the unconjugated small molecule tyrosine kinase inhibitors.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2000
Accession Number
ADA390099

Entities

People

  • Roland Gunther

Organizations

  • University of Minnesota

Tags

DTIC Thesaurus Topics

  • Biological Therapy
  • Breast Cancer
  • Cell Physiological Processes
  • Cells
  • Cellular Structures
  • Chemical Analysis
  • Chemical Synthesis
  • Chemistry
  • Confocal Microscopy
  • Detectors
  • Liquid Chromatography
  • Mass Spectrometry
  • Medical Personnel
  • Peptide Growth Factors
  • Peripheral Nervous System

Readers

  • Analytical Chemistry
  • Cellular and Molecular Pathways of Apoptosis.
  • Prostate Cancer Biology.